Chardan Capital Thinks Achilles Therapeutics’ Stock is Going to Recover
May 02 2022 - 08:15AM
TipRanks
Chardan Capital analyst Keay Nakae reiterated a Buy rating on
Achilles Therapeutics (ACHL – Research Report) today. The company's
shares closed last Friday at $2.22, close to its 52-week low of
$2.11. According to TipRanks.com, Nakae is a 4-star analyst with an
average return of 8.1% and a 38.8% success rate. Nakae covers the
Healthcare sector, focusing on stocks such as Sonnet
BioTherapeutics Holdings, Mountain Crest Acquisition II, and
Arrowhead Pharmaceuticals. Achilles Therapeutics has an analyst
consensus of Strong Buy, with a price target consensus of
$19.50.
https://www.tipranks.com/news/blurbs/chardan-capital-thinks-achilles-therapeutics-stock-is-going-to-recover-3?utm_source=advfn.com&utm_medium=referral
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Jul 2022 to Aug 2022
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Aug 2021 to Aug 2022